Clinical trials: multiple sclerosis
Multiple Sclerosis
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in MS patients 55 or older.
- Trial name
- DISCOMS (NCT03073603)
- Testing
- Discontinuation of disease modifying therapy, Standard of Care
- Where
- 19 sites in United States
- Volunteers
- 259 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
Psychometric Properties Mobility Measures MS
Current study will investigate the quality (psychometric properties) and clinical utility of several mobility measures, according to disability level.
- Trial name
- MCS-III-MOB (NCT02339688)
- Testing
- conventional MS rehabilitation
- Where
- Belgium
- Volunteers
- 254 people
- Sponsor
- Hasselt University
Multiple Sclerosis, Relapsing-Remitting
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
This is an exploratory study, which allows analysis of multiple immune parameters derived from peripheral blood mononuclear cells (PBMCs) from patients with relapsing remitting multiple sclerosis before and during…
- Trial name
- DIMAT-MS (NCT02461069)
- Testing
- Dimethyl fumarate
- Where
- 6 sites in Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Relapse-remitting Multiple Sclerosis
Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis
The purpose of this study is to study the effect of fingolimod on cardiac autonomic regulation in patients with relapse-remitting multiple sclerosis.
- Trial name
- FingoHRV (NCT01704183)
- Where
- 2 sites in Finland
- Volunteers
- 27 people
- Sponsor
- Kuopio University Hospital
Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating…
- Conditions
- Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases
- Trial name
- OCR-VAX (NCT04837651)
- Testing
- Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dragonfly Research, LLC
Multiple Sclerosis
Common and Specific Information From Neuroimaging and Smartphone
Gait alteration is frequent in MS and limitation in walking ability is a major concern in MS patients. Umanit and LMJL (Nantes university) has developed a device call egait to assess walking ability in individuals (eg MS…
- Trial name
- MS-CSI (NCT05482906)
- Testing
- eGait
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Multiple Sclerosis
Cut-Off Values for Gait and Balance in MS
Purpose of the Study: The aim of this study is to determine the cut-off values of gait variability and limits of stability-postural sways scores in patients with MS in order to identify fall risk at an early stage and take…
- Trial name
- NCT07151547
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Hacettepe University
Multiple Sclerosis, Urinary Bladder, Overactive
Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study
The goal is to investigate the feasibility and effects of adding "wearables for the bladder" devices to conventional pelvic floor physical therapy (PFPT) to bladder function, in people with multiple sclerosis (MS).
- Trial name
- WeB (NCT05715268)
- Testing
- WeB, Standard pelvic floor physical therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?
Over the last 20 years, there have been many studies investigating the efficacy of attention and memory rehabilitation for people with multiple sclerosis (MS) however, there appears to be a lack of conclusive evidence regarding…
- Trial name
- NCT05509426
- Testing
- Cognitive Rehabilitation
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Nottingham
Multiple Sclerosis
GSK2018682 FTIH in Healthy Volunteers
This protocol describes the first administration of GSK2018682 to humans. The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of GSK2018682.
- Trial name
- P1A114070 (NCT01387217)
- Testing
- GSK2018682
- Where
- 2 sites in Australia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis
- Trial name
- IMPAMS (NCT01214317)
- Testing
- plasmapheresis
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences
Parkinson Disease, Multiple Sclerosis
Reliability and Validity Studies of Turkish Version of Manual Ability Measure-36
This study aim was to investigate the validity and reliability of Turkish version of Manual Ability Measure-36 (MAM-36) in patients with neurological disease.
- Conditions
- Parkinson Disease, Multiple Sclerosis, Stroke, Upper Extremity Problem
- Trial name
- NCT06122740
- Testing
- Turkish Validity and Reliability of The MAM-36 Scale
- Volunteers
- 250 people
- Sponsor
- Istanbul Medeniyet University
Multiple Sclerosis
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
This study is to identify the safety and efficacy of repeat IV(Intravenous) and IT(Intrathecal) administrations of UMSC01 in patients with MS.
- Trial name
- UMSC01 (NCT05532943)
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Multiple Sclerosis
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
This study will evaluate the evolution of leptomeningeal lesions via leptomeningeal contrast enhancement (LMCE) presence/disappearance after treatment administration in patients with active progressive multiple sclerosis (MS).
- Trial name
- LEGATO (NCT05208840)
- Testing
- Ocrelizumab
- Where
- 2 sites in Russia
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Improving Prospective Memory Via Telehealth
Up to 70% of persons with multiple sclerosis (PwMS) experience cognitive impairment, which can have a significant impact on several aspects of their daily lives.
- Trial name
- TPMI (NCT05129293)
- Testing
- Prospective Memory Intervention, Educational
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Trinity Health Of New England
Multiple Sclerosis
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.
- Trial name
- NCT02326935
- Testing
- Autologous adipose derived mesenchymal cells
- Where
- Cayman Islands
- Volunteers
- 2 people
- Sponsor
- American CryoStem Corporation
Multiple Sclerosis, Fatigue
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
This study assesses the safety, tolerability, and efficacy of suvorexant in multiple sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment period 1 with either suvorexant or matching placebo…
- Conditions
- Multiple Sclerosis, Fatigue, Insomnia
- Trial name
- DREAM (NCT03110315)
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Theodore R. Brown, MD MPH
Multiple Sclerosis
This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, [18F]-FZTA, to detect inflammation in the brain.
- Trial name
- FZTA Pilot (NCT07115017)
- Testing
- [18F] FZTA
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis
The current study sought to prolong the observational interval after initiating medication with fingolimod and to measure the long-term effects of fingolimod on HR and HRV as an indicator of autonomic nervous system function in…
- Trial name
- FINGORHYMS (NCT03216915)
- Testing
- Gilenya®; Novartis Pharmaceuticals Corporation
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis, Healthy
Walking Fatigability and Brain Activity in People With Multiple Sclerosis
Walking fatigability is a motor impairment happening in approximately 43.5% of people with multiple sclerosis (pwMS). Walking fatigability is defined as a decrease in 10% of distance walked, comparing the first minute with the…
- Trial name
- NCT06672484
- Where
- 3 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hasselt University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.